LentiGlobin BB305: Additional Ph I/II Northstar (HGB-204) data

Additional data from the open-label, international Phase I/II Northstar (HGB-204) trial evaluating LentiGlobin BB305 showed that all 5 patients with non-beta-0/beta-0 genotype and ≥12 months of follow-up were transfusion independent, with

Read the full 313 word article

User Sign In